Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Efavirenz for Patients With Alzheimer's Disease
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 5
- Registration Number
- NCT03706885
- Locations
- 🇺🇸
University Hospitals Brain Health and Memory Center, Beachwood, Ohio, United States
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 28
- Registration Number
- NCT03532425
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
- Conditions
- Drug InteractionContraceptive UsageHIV Infections
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 148
- Registration Number
- NCT03336346
- Locations
- 🇧🇼
Botswana-UPenn Partnership, Gaborone, Botswana
Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV
- Conditions
- EfavirenzMedication AdherenceChild BehaviorDrug-Related Side Effects and Adverse ReactionsCognitive Symptom
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT03227653
- Locations
- 🇹🇿
Mawenzi Regional Hospital, Moshi, Kilimanjaro Region, Tanzania
🇹🇿Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro Region, Tanzania
🇹🇿Kiboroloni Dispensary, Moshi, Tanzania
Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
- Conditions
- HIV/AIDS
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2023-09-13
- Target Recruit Count
- 721
- Registration Number
- NCT03178084
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Professor Francois Venter
- Target Recruit Count
- 1110
- Registration Number
- NCT03122262
- Locations
- 🇿🇦
Wits RHI Yeoville Clinic, Johannesburg, Gauteng, South Africa
🇿🇦Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦Shandukani Research Centre, Johannesburg, Gauteng, South Africa
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2022-11-21
- Target Recruit Count
- 643
- Registration Number
- NCT03048422
- Locations
- 🇧🇼
Molepolole CRS, Gaborone, Botswana
🇹🇭Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand
🇿🇼St Mary's CRS, Chitungwiza, Zimbabwe
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02945163
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇨🇳Yunnan provincial infectious disease hosipital, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
Optimization of Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02935075
- Locations
- 🇨🇳
Yunnan AIDS care center, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
- Conditions
- HIV
- Interventions
- Drug: tenofovir/lamivudineDrug: Rifinah or local generics
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 35
- Registration Number
- NCT02832778
- Locations
- 🇺🇬
Infectious Diseases Insitute, Kampala, P.O. Box 22418, Uganda
🇬🇧Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.